

APPENDIX 3- R&D Finances 2020/21

| | Anticipated | Actual |
|--|---------------------|-----------------------|
| | Income £ | Income £ |
| Health & Care Research Wales Portfolio studies | 2,300,000 | 2,300,000 |
| Joint Clinical Research Facility commercial income | 800,000 | 500,000 |
| Cancer institute commercial Income | 500,000 | 400,000 |
| | <u>3,600,000</u> | <u>3,200,000</u> |
| Income shortfall | | <u>400,000</u> |
| <u>Recovery / Mitigation</u> | | |
| Research staff redeployed for several months 2.0 wte to Cardiac ITU, 1.0 wte to Neonatal ITU | | 20,000 |
| Potential loss of income submitted on HB Risk Register covered by central UK COVID funding for staff employed on UHP studies | | 150,000 |
| Staff on long term sick/ Maternity Leave / vacancies no cover requested and vacancies held due to Pandemic | | 40,000 |
| Commercial income invoiced April to July 2020, for work taking place in Jan – March 2020. Delays due to gateways in contracts and for company agreements of work completed | | 120,000 |
| Commercial COVID trials, in particular MEDICAGO trial. Income generated £200,000, but extra costs incurred against this for Medic payments, Patient fees, Pharmacy and Pathology tests, leaving a contribution to R&D bottom line of:- | | 70,000 |
| | | <u>400,000</u> |